MedicalResearch.com Interview with:
Prof Jean-Michel Molina
Maladies Infectieuses et Tropicales, Hôpital
Saint-Louis, Paris France
Medical Research: What is the background for this study? What are the main findings?
Prof. Molina: Treatment of co-infected
patients is complicated by drug drug interactions with HIV drugs, and
the news DAAs are not very potent on HCV G2 and 3 infections.
Medical Research: What should clinicians and patients take away from your report?
Prof. Molina: The simple combination of
sofosbuvir plus ribavirin (available as a generic drug) provides potent
response rates above 80% for co-infected patients with all genotypes,
with limited drug drug interactions with HIV drugs.
Labels: HIV-HCV coinfection; treatment; medications; disease management; disease progression, PHOTON-2